In the current study, we administered two well-studied mitochondria-targeted antioxidants, MitoQ and MitoTEMPO, to mice with BRAF-induced malignant melanoma and KRAS-induced lung cancer, and defined their impact on tumor progression and metastasis. Here, KRAS is linked to melanoma.